Q1 Earnings Estimate for CRSP Issued By Leerink Partnrs

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($1.33) for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.26) EPS, Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($5.17) EPS.

Several other equities analysts have also recently weighed in on CRSP. Bank of America dropped their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Wednesday. Chardan Capital reiterated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday. Finally, JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $76.11.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $43.30 on Thursday. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. The company’s 50 day moving average price is $42.06 and its two-hundred day moving average price is $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

Insider Activity

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the third quarter worth $43,000. Finally, Eastern Bank acquired a new position in CRISPR Therapeutics in the third quarter valued at $70,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.